Table 2 Intake of antiherpetic drugs during follow-up. ‶Echantillon Généraliste des Bénéficiaires.″ 2009–2017
From: Antiherpetic drugs: a potential way to prevent Alzheimer’s disease?
Study sample N=68291, N (%) | Systemic antiherpetic drugs (N=6642), N (%) | |
|---|---|---|
Antiherpetic drugs | 9650 (14.13) | |
Systemic antiherpetic drugs | 6642 (9.73) | 6642 (100.00) |
J05AB01 Aciclovir | 1101 (1.61) | 1101 (16.58) |
J05AB09 Famciclovir | 26 (0.04) | 26 (0.39) |
J05AB11 Valaciclovir | 5879 (8.61) | 5879 (88.51) |
J05AB14 Valganciclovir | 17 (0.02) | 17 (0.26) |
Number of deliveries during follow-up, median [IQR], p90 and p95 | 1 [1–2], 7 and 16 | |
Number of deliveries per year of follow-up, median [IQR], p90 and p95 | 0.12 [0.11–0.33], 1 and 2.3 | |
≥ 2 deliveries per year of follow-up | 169 (0.25) | 169 (2.54) |
Nonsystemic antiherpetic drugs | 5375 (7.87) | 2367 (35.64) |
Dermatological application | 4903 (7.18) | 2067 (31.12) |
D06BB03 Aciclovir | 4903 (7.18) | 2067 (31.12) |
Ophthalmological application | 615 (0.90) | 420 (6.32) |
S01AD02 Trifluridine | 93 (0.14) | 39 (0.59) |
S01AD03 Aciclovir | 341 (0.50) | 267 (4.02) |
S01AD09 Ganciclovir | 247 (0.36) | 167 (2.51) |